HBOT Conversations:
Dr. Paul Harch & Inflammation
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on Inflammation is the first in a 9 episode series that will be released weekly with Dr. Harch.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with special guest and HBOT expert, Dr. Paul G. Harch, MD. This is the first of nine episodes with Dr. Harch examining the God-given miracle of Hyperbaric Oxygen Therapy.
In this episode, we dive into how HBOT is a game-changer for inflammation. Harch explains that inflammation is the driving factor for countless chronic illnesses, but thankfully Hyperbaric Oxygen Therapy is a natural proven way to suppress inflammation.
Harch summarizes a fascinating study done in 2008, by Dr. Cassandra Godman. Her team took skin biopsies and extracted the normal tissue, then they examined the cells that lined the tiniest blood vessels in the tissue. Next, they put these cells in a petri dish and put them in a hyperbaric chamber and gave him a single hyperbaric treatment. Afterwards, they did a mass gene array analysis for 48 hours. What happened next was ground-breaking in better understanding the role that HBOT has on inflammation.
At the end of 24 hours 8,101 of our 19,000 protein coding genes in our 23 chromosomes were either significantly turned on or turned off & suppressed. That single HBOT treatment turned on the anti-inflammatory genes and the growth and repair hormone genes, and the largest cluster suppressed were the pro-inflammatory genes.
Our inflammatory reaction is inescapable when an injury occurs. But, when the patient receives hyperbaric oxygen therapy treatment after an injury (the sooner the better), it can have an overwhelming positive influence on the inflammatory reaction at any place along the spectrum. Harch continues to explain that the anti-inflammatory effects of hyperbaric oxygen are wide-ranging.
Harch spoke of the Navy’s experience with Hyperbaric Oxygen Therapy, as the Navy really kind of dominated this field for many years. The Navy reported that if you can get someone in a chamber within one hour of coming out of the water – when they’re symptomatic for decompression sickness – then the first hyperbaric treatment is curative in 90% of cases. Everyone thought that HBOT was treating bubbles in the brain at that point, but the reality is they were treating inflammation. We now know that it’s the inflammatory reaction in the brain after the bubbles passed that Hyperbaric Oxygen Therapy is treating; not the bubbles.
HBOT isn’t new, it dates back well over a hundred years. It’s still misunderstood, because many believe that HBOT therapy is a treatment for diseases. But, the reality is that HBOT is a treatment for disease processes, and it’s these processes that cause the diseases. We treat the inflammation that causes the disease processes, and in turn we treat the disease. That’s the power of Hyperbaric Oxygen Therapy.
Stay tuned for all nine episodes that will be release each Friday for the next eight weeks.
Guest
Dr. Paul G. Harch, MD
Dr. Paul G. Harch, M.D. is a clinician in emergency medicine and hyperbaric medicine who is the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Currently, he is a Clinical Professor of Medicine in the Section of Emergency Medicine at LSU School of Medicine in New Orleans. He graduated from the Johns Hopkins University School of Medicine after graduating from the University of California at Irvine with magna cum laude/Phi Beta Kappa honors.
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Subscribe Now, It’s Free !
Recent HBOT News
Healing of spongiosus-cutaneous fistula with Hyperbaric Oxygen Therapy (HBOT): a case report.
Abstract: We present a case of a spongiosus-cutaneous fistula in a 39-year-old man with recurrent episodes of cutaneous abscess in dorsal middle third penis (5 - 3 cm) treated with Hyperbaric Oxygen Therapy (HBOT). After emptying nodular abscess, the patient was...
Clinical Trial – Caudal Block,Saddle Block, Anorectal Surgery
Anorectal surgery includes pilonidal sinus, hemorrhoidectomy, anal fissure, and anal fistula
operations. Various surgical and anesthetic techniques have been used to increase the level
of analgesia in perioperative period and decrease the length of stay in the hospital. In this
study, investigators investigate the effects of routinely applied anesthesia techniques
during anorectal surgery, caudal block and saddle block, on patients’ perioperative
hemodynamic values, sensory and motor block levels, and postoperative pain scores.
Clinical Trial – Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with recurrent
mucosal inflammation. Clinically, the disease is characterized by bloody diarrhea, abdominal
pain, and constitutional symptoms such as fever and weight loss. Treatment strategies vary
based on disease activity and target various aspects of the inflammatory cascade. Options
include: anti-inflammatory drugs (mesalamine), immunosuppressive or modulatory medications
(corticosteroids, thiopurines, cyclosporine) and biologic agents (Anti-TNF). Disease severity
can be wide ranging, and nearly 25% of UC patients are hospitalized for acute severe disease.
Of these patients, 30% will undergo colectomy after the acute episode, a quarter of which
will experience post-operative complications. Although there has been great progress in
treatment of UC over the past decade, even with the anti-TNF agent infliximab, the one-year
remission rate for patients not responding to conservative management is barely 20%.
Furthermore, corticosteroids have significant long-term consequences and immune suppressive
drugs such as 6-mercaptopurine, azathioprine and infliximab have been associated with serious
adverse events including life-threatening infections and lymphomas. With growing evidence
that the pathogenesis of UC is multi-factorial and involves a complex interaction of genetic
and environmental factors, newer treatment modalities are being evaluated to target the
mucosal immune response and mucosal inflammatory regulatory system.
Hyperbaric oxygen offers a promising new treatment option since it targets both tissue
hypoxia and inflammation. Recent small scales studies evaluating the impact of hyperbaric
oxygen treatment in acute ulcerative colitis flares demonstrated improved outcomes. The
mechanisms underlying the improvement are not known. In this study, we will treat ulcerative
colitis flares with hyperbaric oxygen and measure changes in both markers of tissue hypoxia
and inflammation. We hypothesize that hyperbaric oxygen will (a) improve outcomes, and (b)
show reductions in markers of both tissue hypoxia and inflammation.